

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

MINERALYS THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

603170101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 603170101

1	Names of Reporting Persons Andera Partners
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,765,976.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,765,976.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,765,976.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.2 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

CUSIP No.	603170101
-----------	-----------

1	Names of Reporting Persons BioDiscovery 6 FPCI	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization FRANCE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,765,976.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,765,976.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,765,976.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	

11	Percent of class represented by amount in row (9) 4.2 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP No.	603170101
-----------	-----------

1	Names of Reporting Persons Stephane Bergez	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization FRANCE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,765,976.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,765,976.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,765,976.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.2 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

CUSIP No.	603170101
-----------	-----------

1	Names of Reporting Persons Francois Xavier Mauron
---	--

2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization FRANCE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,765,976.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,765,976.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,765,976.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.2 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

Item 1.

- (a) **Name of issuer:**
MINERALYS THERAPEUTICS, INC.
- (b) **Address of issuer's principal executive offices:**
150 N. Radnor Chester Road, Suite F200, Radnor, PA, 19087.

Item 2.

- (a) **Name of person filing:**
 The names of the persons filing this report (collectively, the "Reporting Persons") are:
 BioDiscovery 6 FPCI ("BioDiscovery 6")
 Andera Partners ("Andera")
 Stephane Bergez ("Bergez")
 Francois Xavier Mauron ("Mauron")
 The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (b) **Address or principal business office or, if none, residence:**
 2 place de Rio de Janeiro
 75008 Paris
 France
- (c) **Citizenship:**
 BioDiscovery 6 France
 Andera France
 Bergez France
 Mauron France

(d) **Title of class of securities:**
Common Stock, \$0.0001 par value per share

(e) **CUSIP No.:**
603170101

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) **Amount beneficially owned:**

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

BioDiscovery 6 is the record holder of 2,765,976 shares of common stock. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6.

(b) **Percent of class:**

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 65,175,287 shares of common stock outstanding as of May 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2025.

%

(c) **Number of shares as to which the person has:**

(i) **Sole power to vote or to direct the vote:**

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

(ii) **Shared power to vote or to direct the vote:**

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

(iii) **Sole power to dispose or to direct the disposition of:**

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

☒ Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Andera Partners

Signature: /s/ Stephane Bergez
Name/Title: By Stephane Bergez, Managing Partner
Date: 08/14/2025

BioDiscovery 6 FPCI

Signature: /s/ Stephane Bergez
Name/Title: By Andera Partners, its management company, By Stephane Bergez, Managing Partner
Date: 08/14/2025

Stephane Bergez

Signature: /s/ Stephane Bergez
Name/Title: Stephane Bergez
Date: 08/14/2025

Francois Xavier Mauron

Signature: /s/ Francois Xavier Mauron
Name/Title: Francois Xavier Mauron
Date: 08/14/2025

Exhibit Information

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Mineralys Therapeutics, Inc. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as August 14, 2025.

Andera Partners

By: /s/ Stephane Bergez
Name: Stephane Bergez
Title: Managing Partner

BioDiscovery 6 FPCI

By: Andera Partners
Its: Management Company

By: /s/ Stephane Bergez
Name: Stephane Bergez
Title: Managing Partner

Stephane Bergez

/s/ Stephane Bergez -

François Xavier Mauron

/s/ François Xavier Mauron -